Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.

Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2019 Dec 24. pii: S1083-8791(19)31674-X. doi: 10.1016/j.bbmt.2019.12.726. [Epub ahead of print]

PMID:
31881283
2.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR.

Lancet Haematol. 2020 Feb;7(2):e112-e121. doi: 10.1016/S2352-3026(19)30210-8. Epub 2019 Dec 19.

PMID:
31866281
3.

Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.

Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2019 Nov 29. pii: S1083-8791(19)30834-1. doi: 10.1016/j.bbmt.2019.11.028. [Epub ahead of print]

PMID:
31786242
4.

Site-Specific Protein Photochemical Covalent Attachment to Carbon Nanotube Side Walls and Its Electronic Impact on Single Molecule Function.

Thomas SK, Jamieson WD, Gwyther REA, Bowen BJ, Beachey A, Worthy HL, Macdonald JE, Elliott M, Castell OK, Jones DD.

Bioconjug Chem. 2020 Jan 7. doi: 10.1021/acs.bioconjchem.9b00719. [Epub ahead of print]

PMID:
31743647
5.

Bombardier beetles of the genus Pheropsophus Solier 1833 (Carabidae: Brachininae: Brachinini) from Indian subcontinent.

Venugopal AS, Thomas SK.

Zootaxa. 2019 May 17;4608(1):zootaxa.4608.1.3. doi: 10.11646/zootaxa.4608.1.3.

PMID:
31717160
6.

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ.

Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. No abstract available.

7.

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM.

Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4. No abstract available.

PMID:
31489991
8.

Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.

Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH.

Clin Cancer Res. 2019 Nov 15;25(22):6781-6787. doi: 10.1158/1078-0432.CCR-19-0706. Epub 2019 Sep 3.

PMID:
31481508
9.

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ.

Haematologica. 2019 Aug 14. pii: haematol.2019.225375. doi: 10.3324/haematol.2019.225375. [Epub ahead of print]

10.

Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia.

Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK.

Ann Hematol. 2019 Sep;98(9):2233-2235. doi: 10.1007/s00277-019-03734-7. Epub 2019 Jun 26. No abstract available.

PMID:
31243571
11.

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.

Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):560-569. doi: 10.1016/j.clml.2019.05.001. Epub 2019 May 17.

PMID:
31201134
12.

Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?

Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e465-e469. doi: 10.1016/j.clml.2019.04.015. Epub 2019 May 2.

PMID:
31133526
13.

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.

Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK.

Leukemia. 2019 Dec;33(12):2924-2933. doi: 10.1038/s41375-019-0482-0. Epub 2019 May 15.

PMID:
31092894
14.

Mechanical activation of noncoding-RNA-mediated regulation of disease-associated phenotypes in human cardiomyocytes.

Kumar A, Thomas SK, Wong KC, Lo Sardo V, Cheah DS, Hou YH, Placone JK, Tenerelli KP, Ferguson WC, Torkamani A, Topol EJ, Baldwin KK, Engler AJ.

Nat Biomed Eng. 2019 Feb;3(2):137-146. doi: 10.1038/s41551-018-0344-5. Epub 2019 Jan 28.

15.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH.

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

PMID:
30910541
16.

Hepatocytes direct the formation of a pro-metastatic niche in the liver.

Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL.

Nature. 2019 Mar;567(7747):249-252. doi: 10.1038/s41586-019-1004-y. Epub 2019 Mar 6.

17.

Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.

Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK.

Am J Hematol. 2019 Mar;94(3):E72-E74. doi: 10.1002/ajh.25375. Epub 2018 Dec 21. No abstract available.

PMID:
30548467
18.

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ.

Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.

PMID:
30501870
19.

Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany.

Mayerhoff L, Lehne M, Hickstein L, Salimullah T, Prieur S, Thomas SK, Zhang J.

J Comp Eff Res. 2019 Jan;8(2):121-131. doi: 10.2217/cer-2018-0100. Epub 2018 Dec 5.

20.

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.

Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH.

Bone Marrow Transplant. 2019 Jul;54(7):1089-1093. doi: 10.1038/s41409-018-0392-1. Epub 2018 Nov 16.

PMID:
30446740
21.

Taxonomy of Euschizomerus Chaudoir 1850 (Coleoptera: Carabidae: Panagaeinae) from India with a new species and new synonym.

Jithmon VA, Thomas SK.

Zootaxa. 2018 Sep 5;4471(2):361-368. doi: 10.11646/zootaxa.4471.2.8.

PMID:
30313410
22.

Melphalan-based autologous transplant in octogenarian multiple myeloma patients.

Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH.

Am J Hematol. 2019 Jan;94(1):E2-E5. doi: 10.1002/ajh.25310. Epub 2018 Oct 31. No abstract available.

23.

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.

Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ.

Clin Cancer Res. 2018 Dec 15;24(24):6408-6420. doi: 10.1158/1078-0432.CCR-17-3265. Epub 2018 Aug 20.

24.

Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.

Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ.

Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27.

25.

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW.

BMC Cancer. 2018 Feb 13;18(1):187. doi: 10.1186/s12885-018-4094-2.

26.

Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.

Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L.

Leuk Lymphoma. 2018 May;59(5):1133-1142. doi: 10.1080/10428194.2017.1375100. Epub 2017 Sep 21.

PMID:
28933643
27.

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.

Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2018 Feb;59(2):515-518. doi: 10.1080/10428194.2017.1344906. Epub 2017 Jul 3. No abstract available.

PMID:
28673185
28.

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.

Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X.

Mod Pathol. 2017 Oct;30(10):1378-1386. doi: 10.1038/modpathol.2017.63. Epub 2017 Jun 30.

29.

Clinical Presentation and Anatomical Location of Orbital Plasmacytomas.

Thuro BA, Sagiv O, Shinder R, Debnam JM, Ozgur O, Ng JD, Rootman D, Thomas SK, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2018 May/Jun;34(3):258-261. doi: 10.1097/IOP.0000000000000939.

PMID:
28582371
30.

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ.

Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.

31.

Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X.

Mod Pathol. 2017 Jun;30(6):843-853. doi: 10.1038/modpathol.2017.3. Epub 2017 Mar 10.

32.

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.

Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott-Schwartz J, Restifo NP, Siegel RM.

Nat Commun. 2016 Dec 23;7:13895. doi: 10.1038/ncomms13895.

33.

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.

Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2159-2164. doi: 10.1016/j.bbmt.2016.09.003. Epub 2016 Sep 13.

34.

Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

Maziarz RT, Guérin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.

Int J Hematol Oncol. 2016 Sep;5(2):63-75. doi: 10.2217/ijh-2016-0001. Epub 2016 Apr 27.

35.

Help Desk Answers: What's the most effective topical Tx for scalp psoriasis?

Thomas SK, Hamilton T.

J Fam Pract. 2016 Jun;65(6):412-21.

PMID:
27474825
36.

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ.

Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28.

37.

Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy.

Mahale P, Thomas SK, Kyvernitakis A, Torres HA.

Open Forum Infect Dis. 2015 Dec 28;3(1):ofv211. doi: 10.1093/ofid/ofv211. eCollection 2016 Jan.

38.

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.

Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ.

Blood Cancer J. 2016 Feb 12;6:e396. doi: 10.1038/bcj.2016.4.

39.

Structural Basis and Functional Role of Intramembrane Trimerization of the Fas/CD95 Death Receptor.

Fu Q, Fu TM, Cruz AC, Sengupta P, Thomas SK, Wang S, Siegel RM, Wu H, Chou JJ.

Mol Cell. 2016 Feb 18;61(4):602-613. doi: 10.1016/j.molcel.2016.01.009. Epub 2016 Feb 4.

40.

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.

Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Eur J Haematol. 2016 Oct;97(4):342-7. doi: 10.1111/ejh.12736. Epub 2016 Feb 15.

PMID:
26773409
41.

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH.

Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):36-42. doi: 10.1016/j.clml.2015.11.005. Epub 2015 Dec 1.

PMID:
26702475
42.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP.

J Clin Invest. 2016 Jan;126(1):318-34. doi: 10.1172/JCI81217. Epub 2015 Dec 14.

43.

Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.

Alfaraj WA, Cachia D, Tummala S, Thomas SK, Manasanch EE.

Ann Hematol. 2016 Jan;95(2):347-8. doi: 10.1007/s00277-015-2516-7. Epub 2015 Oct 3. No abstract available.

PMID:
26432713
44.

Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.

Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH.

Leuk Lymphoma. 2016 May;57(5):1104-13. doi: 10.3109/10428194.2015.1096357. Epub 2015 Dec 23.

PMID:
26421453
45.

Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.

Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS.

J Pain. 2015 Oct;16(10):1032-43. doi: 10.1016/j.jpain.2015.07.002. Epub 2015 Jul 22.

46.

Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.

Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH.

J Hematol Oncol. 2015 Jun 24;8:74. doi: 10.1186/s13045-015-0172-y.

47.

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.

Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ.

Clin Cancer Res. 2015 Jun 1;21(11):2538-45. doi: 10.1158/1078-0432.CCR-14-1462. Epub 2015 Mar 6.

48.

Multiple drug intolerance syndrome: a large-scale retrospective study.

Omer HM, Hodson J, Thomas SK, Coleman JJ.

Drug Saf. 2014 Dec;37(12):1037-45. doi: 10.1007/s40264-014-0236-x.

49.

How Does Uncertainty Around Costs And Effects Relate To Uncertainty Around Cost-Effectiveness?

Jain M, Bhattacharyya S, Gupta S, Sonathi V, Mahon R, Malakar H, Vudumala U, Gunda P, Kumar P, Partha G, Thomas SK.

Value Health. 2014 Nov;17(7):A561-2. doi: 10.1016/j.jval.2014.08.1858. Epub 2014 Oct 26. No abstract available.

50.

A DE-NOVO Model to Predict Outcomes of a New Hypothetical Intervention to Reduce CV Risk in Post Mi Patients.

Jain M, Sonathi V, Rathi H, Bakuli A, Thomas SK, Mollon P.

Value Health. 2014 Nov;17(7):A558. doi: 10.1016/j.jval.2014.08.1837. Epub 2014 Oct 26. No abstract available.

Supplemental Content

Loading ...
Support Center